Amgen Inc. (AMGN) FY2025 Q3 Balance Sheet

Amgen Inc. (AMGN) FY2025 Q3 Balance Sheet

Balance sheet as of 2025-09-30. The chart shows assets, liabilities and equity at that date.

Assets

90,141,000,000 US dollars

Current assets

27,885,000,000 US dollars

Non-current assets

62,256,000,000 US dollars

Liabilities (calculated)

80,522,000,000 US dollars

Current liabilities

21,791,000,000 US dollars

Non-current liabilities

58,731,000,000 US dollars

Equity

9,619,000,000 US dollars

Cash and cash equivalents

9,445,000,000 US dollars

Trade receivables, net

8,490,000,000 US dollars

Inventories

6,346,000,000 US dollars

Other current assets

3,604,000,000 US dollars

Intangible assets, net

23,139,000,000 US dollars

Goodwill

18,676,000,000 US dollars

Other noncurrent assets

13,221,000,000 US dollars

Property, plant and equipment, net

7,220,000,000 US dollars

Accrued liabilities

16,800,000,000 US dollars

Accounts payable

2,838,000,000 US dollars

Current portion of long-term debt

2,153,000,000 US dollars

Long-term debt

52,434,000,000 US dollars

Long-term tax liabilities

2,616,000,000 US dollars

Other noncurrent liabilities

2,223,000,000 US dollars

Long-term deferred tax liabilities

1,458,000,000 US dollars

Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—538.5 shares in 2025 and 536.9 shares in 2024

33,841,000,000 US dollars

Accumulated deficit

negative 23,800,000,000 US dollars

Accumulated other comprehensive loss

negative 422,000,000 US dollars

Gross equity (calculated)

33,841,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.